Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?

CEO Jon Congleton sold 75,000 shares for a total transaction value of ~$1.97 million on April 2, 2026. The sale represented 9.61% of direct holdings prior to the transaction, reducing direct ownership to 705,051 shares.